Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
Authors:
Open Access
- 29 November 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9, 1372
Abstract
Objective: The aim of this study was to explore the tolerance, variability, and pharmacokinetics (PK) of albumin-bound paclitaxel (QL, HR, ZDTQ) among Chinese breast cancer patients. Methods: Three randomized, open-label, two-period crossover bioequivalence studies were conducted with albumin-bound paclitaxel. Each subject received a single dose of 260 mg/m2 albumin-bound paclitaxel [sponsor 1 (QL, light food), sponsor 2 (HR, fasting), sponsor 3 (ZDTQ, light food); test] or Abraxane® (reference) and was monitored for 72 h. Serum concentrations of total paclitaxel and unbound paclitaxel were measured using liquid chromatography/mass spectrometry (LC/MS), and appropriate pharmacokinetic parameters were determined by non-compartmental methods. Safety assessments included adverse events, hematology and biochemistry tests. Results: The bioequivalence analyses of the QL, HR, and ZDTQ products included 24, 23, and 24 patients, respectively. The mean t1/2 was 20.61–27.31 h for total paclitaxel. Food intake did not affect the pharmacokinetics of paclitaxel. From the comparison of total paclitaxel and unbound paclitaxel, the 90% confidence intervals (CIs) for the ratios of Cmax, AUC0−t, and AUC0−∞ were within 80.00–125.00%. The intra-subject variability ranged from 6.4–11% to 9.85–15.87% for total paclitaxel and unbound paclitaxel, respectively. Almost all subjects in the test and Abraxane® (reference) groups experienced mild or moderate adverse events. No fatal AEs or study drug injection site reactions related to these drugs were observed. Conclusion: Albumin-bound paclitaxel (QL, HR or ZDTQ; test products) showed bioequivalence to Abraxane® (reference) with lower intra-subject variability, which was less than 16% in all cases, and was well-tolerated in Chinese breast cancer patients. Twenty-two patients are enough for an albumin-bound paclitaxel bioequivalence study.Keywords
This publication has 30 references indexed in Scilit:
- Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumorsCritical Reviews in Oncology/Hematology, 2014
- Prevention and handling of acute allergic and infusion reactions in oncologyAnnals of Oncology, 2012
- Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancerExpert Opinion on Pharmacotherapy, 2012
- Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMAPharmaceutical Research, 2011
- Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast CancerClinical Breast Cancer, 2010
- Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxelExpert Opinion on Pharmacotherapy, 2010
- Considerations for Metabolite Pharmacokinetic Data in Bioavailability/Bioequivalence AssessmentsArzneimittelforschung, 2009
- Bioavailability and Bioequivalence: Focus on Physiological Factors and VariabilityPharmaceutical Research, 2008
- Highly Variable Drugs: Observations from Bioequivalence Data Submitted to the FDA for New Generic Drug ApplicationsThe AAPS Journal, 2008
- Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studiesEuropean Journal of Drug Metabolism and Pharmacokinetics, 1991